Literature DB >> 8124222

Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.

C L Sawyers1.   

Abstract

The BCR-ABL translocation of chronic myelogenous leukemia represents a paradigm for the study of translocations that create fusion proteins. The work of many laboratories has clearly established that the BCR-ABL protein can transform cells and cause leukemias in mice. This oncogenic signal appears to involve transduction of a tyrosine kinase signal from the cytoplasm to the nucleus via intermediary proteins such as ras and myc. Although the biological effects of the BCR-ABL fusion protein are well characterized, the normal biological functions of ABL and BCR are only beginning to come to light. ABL is a nuclear tyrosine kinase which binds DNA, suggesting a possible normal role in transcription. BCR has homology to proteins which regulate membrane ruffling. Understanding the normal roles of ABL and BCR will help define the abnormal leukemogenic effects of the BCR-ABL fusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124222     DOI: 10.3109/10428199309064268

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

Review 1.  c-Abl in neurodegenerative disease.

Authors:  Sarah D Schlatterer; Christopher M Acker; Peter Davies
Journal:  J Mol Neurosci       Date:  2011-07-05       Impact factor: 3.444

2.  c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Authors:  Nidal Muvarak; Shannon Kelley; Carine Robert; Maria R Baer; Danilo Perrotti; Carlo Gambacorti-Passerini; Curt Civin; Kara Scheibner; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2015-03-31       Impact factor: 5.852

3.  A rapid RT-PCR based method for the detection of BCR-ABL translocation.

Authors:  L B Saltykova; A A Lyschov; K M Abdulkadyrov; M N Blinov
Journal:  Mol Pathol       Date:  1997-10

4.  Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.

Authors:  Alexandra Mazharian; Cedric Ghevaert; Lin Zhang; Steffen Massberg; Steve P Watson
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

5.  A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics.

Authors:  Xuefeng Gao; J Tyson McDonald; Mamta Naidu; Philip Hahnfeldt; Lynn Hlatky
Journal:  Stem Cells Int       Date:  2014-05-12       Impact factor: 5.443

6.  Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia.

Authors:  S Manteniotis; S Wojcik; P Brauhoff; M Möllmann; L Petersen; J R Göthert; W Schmiegel; U Dührsen; G Gisselmann; H Hatt
Journal:  Cell Death Discov       Date:  2016-01-25

Review 7.  The cell cycle checkpoint inhibitors in the treatment of leukemias.

Authors:  A Ghelli Luserna di Rora'; I Iacobucci; G Martinelli
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388

Review 8.  Targeting DNA Repair Pathways in Hematological Malignancies.

Authors:  Jehad F Alhmoud; Ayman G Mustafa; Mohammed Imad Malki
Journal:  Int J Mol Sci       Date:  2020-10-06       Impact factor: 5.923

9.  The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).

Authors:  Jonathan A Winger; Oliver Hantschel; Giulio Superti-Furga; John Kuriyan
Journal:  BMC Struct Biol       Date:  2009-02-24

Review 10.  Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.

Authors:  Steffen Fuchs; Julian Naderi; Fabienne Meggetto
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.